Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(50.0%)
N/A
3(50.0%)
6Total
Phase 1(3)
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05685303Not ApplicableEnrolling By Invitation

Alleviant ALLAY-HF Study

Role: lead

NCT06812533Not ApplicableEnrolling By Invitation

Alleviant ALLAY-HFrEF Study

Role: lead

NCT04838353Not ApplicableCompleted

Alleviate-HF-2 Study

Role: lead

NCT05133089Phase 1Completed

ALLEVIATE-HFrEF Study

Role: lead

NCT05501652Phase 1Completed

ALLEVIATE-HF-HD Study

Role: lead

NCT04583527Phase 1Completed

Alleviate-HF-1 Study

Role: lead

All 6 trials loaded